CLIA Waiver Consulting for IVD Device Manufacturers
Getting a CLIA waiver is not optional if you want your IVD device used outside a certified lab. Point-of-care clinics, doctor’s offices, pharmacies or none of them can run a moderate-complexity test. So if that is your market, the waiver is the market. Our consultants works with IVD manufacturers on the full waiver process picking the right pathway, designing studies that actually hold up at FDA, and putting together submissions that do not come back with deficiency letters.
We handle both standalone waiver applications and dual 510k submissions. Get in touch if you want a straight answer on where your device stands.
What Is a CLIA Waiver and Why Does It Matter?
A CLIA waiver allows your IVD device to be used in non-laboratory settings doctor’s offices, pharmacies, urgent care clinics, and at home. Without it, your device is restricted to certified clinical labs, which represents a fraction of the potential US market. The waiver is granted by the FDA after you prove your device is simple to use and carries minimal risk of an incorrect result. For most point-of-care diagnostics, it is not a nice-to-have it is what determines whether your commercial launch actually reaches patients.
Who Needs CLIA Waiver Consulting?
You need specialist support if you are launching a new IVD device in the US, expanding an existing cleared device into point-of-care settings, or your waiver application came back with deficiencies. Many manufacturers underestimate the study requirements or choose the wrong submission pathway, submitting standalone when a dual 510k and CLIA waiver approach would have saved six months. If FDA compliance is not your team’s daily job, working with a consultant who knows these submissions inside out is simply faster and less expensive than learning through rejection.
CLIA Waiver Study Design and Clinical Data
The most common reason CLIA waiver applications fail or receive deficiency letters is poor study design not the device itself. We always keep extra force to review the study design even though we are product experts. We look all corners of the study plan when compared with IFU and risk. FDA requires two core studies, first, a comparison study demonstrating your device performs equivalently to a predicate or reference method, and secondly, reproducibility study showing consistent results across different operators, sites, and times. For a dual 510k submission, these studies must satisfy both clearance and waiver requirements simultaneously.
Getting this right means selecting the correct sample types, the right number of sites, appropriate operator profiles that reflect real waived settings, and statistical methods. We help and coordinate with CRO / study moderator to review and comment study design you before a single sample is collected.
The 510(k) and CLIA Process Flow
Why Choose I3CGlobal as Your CLIA Waiver Consultant?
Most regulatory consultants handle CLIA waiver as one service among dozens. At I3CGlobal, IVD regulatory strategy for USA, UKCA and, EUIVDR is our core focus. We have guided two dozens of IVD manufacturers through 510k, and CLIA waiver applications, which means we understand how these pathways interact.
When you work with us, you get a team that has responded to FDA queries, reviewed deficiency letters, redesigned files and got products cleared. We are direct about timelines, realistic about risk, and focused on getting your device to market with the right regulatory status.